Description
Tsc-204-a0101 is an experimental immunotherapy being studied in clinical trials for certain solid tumors, including colorectal cancer. It is a type of T-cell therapy where a patient's own T-cells are modified to better recognize and attack cancer cells. Specifically, this therapy targets the MAGE-A1 protein found on some cancer cells in patients with a specific HLA-A*01:01 genetic type. It is being investigated as a single treatment (monotherapy) or in combination with other similar T-cell therapies (T-Plex combinations) in patients whose tumors have not responded to standard treatments or cannot be surgically removed. The goal is to see if these customized T-cells can shrink tumors or slow their growth.
Mechanism of Action
Tsc-204-a0101 is a type of adoptive cell therapy. It involves collecting a patient's T-cells, modifying them in a lab to express T-cell receptors (TCRs) that specifically recognize the MAGE-A1 protein (a tumor-associated antigen), and then infusing these modified T-cells back into the patient. These engineered T-cells are designed to find and destroy cancer cells that display the MAGE-A1 protein on their surface. The therapy is designed for patients with a specific HLA-A*01:01 genetic marker, which is necessary for the modified T-cells to recognize the target antigen effectively.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.